Occupational Activity
Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients
Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.
Amwell Reports Mixed Q1 Results with Decreased Sales but Narrowed Net Loss
Amwell, Q1 results, sales, net loss, telehealth, digital healthcare
Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity
Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.
Walgreens Expands into Specialty Pharmacy and Therapy Services
Walgreens, specialty pharmacy, drug services, therapy services, healthcare, expansion
Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal
Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal
Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma
Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.
AstraZeneca CEO Pascal Soriot’s Pay Rise Signals Succession Planning
AstraZeneca, Pascal Soriot, CEO, pay rise, succession planning, pharmaceutical industry, executive compensation.
Novartis Boosts 2024 Sales Forecast, Gears Up for Major Cancer Drug Expansions
Novartis, 2024 sales outlook, cancer drugs, drug expansions, pharmaceutical industry, healthcare, oncology.